All In Biotech

Drug Trial Radar · NCT06069544

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

A Randomized, Dose-escalation Phase I/IIa Trial With Controlled Human Malaria Infection to Evaluate Safety, Tolerability, Immunogenicity and Efficacy of an Investigational RNA-based Vaccine for Prevention of P. Falciparum Malaria in Healthy Malaria naïve Adults

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 163 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

163

Actual

Start

Nov 13, 2023

Primary completion

May 28, 2025

Study completion Mar 20, 2026

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
First posted
Oct 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a randomized, dose-escalation Phase I/IIa study to evaluate safety, tolerability, immunogenicity and efficacy of an investigational RNA-based vaccine (BNT165e) for prevention of P. falciparum malaria in healthy malaria-naive adults. The multi-antigen malaria vaccine (designated BNT165e) is a combination of three distinct RNAs, BNT165c and BNT165d (composed of BNT165d1 and BNT165d2), encoding P. falciparum antigens encapsulated in lipid nanoparticles. The BNT165c RNA encodes the full Plasmodium falciparum circumsporozoite protein. The BNT165d1 and BNT165d2 RNAs both encode conserved, immunogenic segments of liver stage-expressed proteins.

Conditions

  • Malaria

Interventions

  • BNT165cBiological

    Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection

  • BNT165dBiological

    Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection

  • PlaceboOther

    Isotonic NaCl solution (0.9%)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and Percentage of Participants With Solicited Local Reactions at the Injection SiteTime frame: Up to 7 days after each IMP dose, (i.e., post-Dose 1, post-Dose 2, and post-Dose 3)
  2. Number and Percentage of Participants With Solicited Systemic ReactionsTime frame: Up to 7 days after each IMP dose, (i.e., post-Dose 1, post-Dose 2, and post-Dose 3)
  3. Number of Participants With at Least One Adverse Event (AE)Time frame: From administration of each IMP dose (i.e., Dose 1, Dose 2, and Dose 3) up to 28 days after the respective IMP dose
  4. Number of Participants With at Least One Medically Attended Adverse Event (MAAE)Time frame: From Dose 1 up to 24 weeks after last received IMP dose, up to 13 months.
  5. Number of Participants With at Least One Serious Adverse Event (SAE)Time frame: From Dose 1 up to 24 weeks after last received IMP dose, up to 13 months.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • AMR Tempe

    Tempe, Arizona

  • University of Maryland, Center for Vaccine Development

    Baltimore, Maryland

  • AMR Las Vegas

    Las Vegas, Nevada

  • AMR Knoxville

    Knoxville, Tennessee

  • Clinical Trials of Texas

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.